Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced its upcoming participation in the UBS Global Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET). Acumen, a clinical-stage biopharmaceutical company, is developing a novel treatment targeting toxic soluble amyloid beta oligomers for Alzheimer's disease. The presentation will be accessible via live webcast on the company's website under the Investors tab and will remain available for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha annunciato la sua prossima partecipazione alla Conferenza Globale sulla Salute UBS. La direzione dell'azienda parteciperà a una chiacchierata informale mercoledì 13 novembre 2024, alle 13:15 PT (16:15 ET). Acumen, un'azienda biofarmaceutica in fase clinica, sta sviluppando un nuovo trattamento mirato agli oligomeri tossici solubili di beta amiloide per l'Alzheimer. La presentazione sarà accessibile tramite un webcast dal vivo sul sito web dell'azienda nella sezione Investitori e rimarrà disponibile per 90 giorni.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha anunciado su próxima participación en la Conferencia Global de Salud de UBS. La dirección de la empresa participará en una charla informal el miércoles 13 de noviembre de 2024, a la 1:15 p.m. PT (4:15 p.m. ET). Acumen, una empresa biofarmacéutica en fase clínica, está desarrollando un nuevo tratamiento dirigido a los oligómeros solubles de beta amiloide tóxicos para la enfermedad de Alzheimer. La presentación estará disponible a través de una transmisión web en vivo en el sitio web de la empresa bajo la pestaña de Inversores y estará accesible durante 90 días.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 다가오는 UBS 글로벌 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 2024년 11월 13일 수요일, 오후 1시 15분 PT(오후 4시 15분 ET)에 화상 대화에 참여할 것입니다. Acumen은 임상 단계의 생명공학 회사로, 알츠하이머병을 위한 독성 용해성 아밀로이드 베타 올리고머를 목표로 하는 새로운 치료법을 개발하고 있습니다. 발표는 회사 웹사이트의 투자자 탭을 통해 실시간 웹캐스트로 상영되며, 90일 동안 제공됩니다.
Acumen Pharmaceuticals (NASDAQ: ABOS) a annoncé sa prochaine participation à la Conférence Mondiale sur la Santé UBS. La direction de l'entreprise participera à une discussion informelle le mercredi 13 novembre 2024, à 13h15 PT (16h15 ET). Acumen, une entreprise biopharmaceutique en phase clinique, développe un nouveau traitement ciblant les oligomères amyloïdes bêta solubles toxiques pour la maladie d'Alzheimer. La présentation sera accessible via un webcast en direct sur le site web de l'entreprise sous l'onglet Investisseurs et restera disponible pendant 90 jours.
Acumen Pharmaceuticals (NASDAQ: ABOS) hat seine bevorstehende Teilnahme an der UBS Global Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird am Mittwoch, den 13. November 2024, um 13:15 Uhr PT (16:15 Uhr ET) an einem informellen Gespräch teilnehmen. Acumen, ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt eine neuartige Behandlung, die auf toxische lösliche amyloide Beta-Oligomere für Alzheimer abzielt. Die Präsentation wird live über eine Webcast auf der Website des Unternehmens unter dem Bereich Investoren verfügbar sein und bleibt 90 Tage lang zugänglich.
- None.
- None.
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET).
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) presenting at the UBS Global Healthcare Conference 2024?
How can I watch Acumen Pharmaceuticals' (ABOS) UBS Conference presentation?
What type of treatment is Acumen Pharmaceuticals (ABOS) developing?
What format will Acumen's (ABOS) presentation take at the UBS Healthcare Conference?
